Genenta Science SPA
NASDAQ:GNTA
Intrinsic Value
Genenta Science SpA engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors. [ Read More ]
The intrinsic value of one GNTA stock under the Base Case scenario is 1.1 USD. Compared to the current market price of 3 USD, Genenta Science SPA is Overvalued by 63%.
Valuation Backtest
Genenta Science SPA
Run backtest to discover the historical profit from buying and selling GNTA stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Genenta Science SPA
Current Assets | 21.3m |
Cash & Short-Term Investments | 18.8m |
Receivables | 2m |
Other Current Assets | 442.8k |
Non-Current Assets | 1.1m |
PP&E | 83k |
Other Non-Current Assets | 1m |
Current Liabilities | 1.7m |
Accounts Payable | 295k |
Accrued Liabilities | 1m |
Other Current Liabilities | 426k |
Non-Current Liabilities | 179.3k |
Other Non-Current Liabilities | 179.3k |
Earnings Waterfall
Genenta Science SPA
Revenue
|
0
EUR
|
Operating Expenses
|
-11.7m
EUR
|
Operating Income
|
-11.7m
EUR
|
Other Expenses
|
87.5k
EUR
|
Net Income
|
-11.6m
EUR
|
Free Cash Flow Analysis
Genenta Science SPA
What is Free Cash Flow?
GNTA Profitability Score
Profitability Due Diligence
Genenta Science SPA's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Genenta Science SPA's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
GNTA Solvency Score
Solvency Due Diligence
Genenta Science SPA's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Genenta Science SPA's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GNTA Price Targets Summary
Genenta Science SPA
According to Wall Street analysts, the average 1-year price target for GNTA is 23.46 USD with a low forecast of 21.21 USD and a high forecast of 26.25 USD.
Shareholder Return
GNTA Price
Genenta Science SPA
Average Annual Return | -24.81% |
Standard Deviation of Annual Returns | 37.65% |
Max Drawdown | -75% |
Market Capitalization | 54.7m USD |
Shares Outstanding | 18 217 000 |
Percentage of Shares Shorted | 0.03% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Genenta Science SpA engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors. The company is headquartered in Milan, Milano and currently employs 4 full-time employees. The company went IPO on 2021-12-15. The firm focuses on the development of lentivirus-based gene and cell therapies in cancer. The company uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The firm not only operates locally but also is present in global markets, including the United States.
Officers
The intrinsic value of one GNTA stock under the Base Case scenario is 1.1 USD.
Compared to the current market price of 3 USD, Genenta Science SPA is Overvalued by 63%.